Review
Biochemistry & Molecular Biology
Christos Vallilas, Panagiotis Sarantis, Anastasios Kyriazoglou, Evangelos Koustas, Stamatios Theocharis, Athanasios G. Papavassiliou, Michalis V. Karamouzis
Summary: Gastrointestinal stromal tumors (GISTs) are the most common types of malignant mesenchymal tumors in the gastrointestinal tract, with treatment options including drugs and immunotherapy, some patients have gene mutations, and drug resistance is becoming more common.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
You-Zhu Wei, Zhi-Bin Cai, Chen-Long Zhu, Yan-Ming Zhou, Xiao-Feng Zhang
Summary: The study evaluated the long-term survival outcomes of patients with duodenal GIST who underwent radical resection (RR) or limited resection (LR). Results showed that surgical modalities did not have a significant impact on long-term survival outcomes, which should mainly depend on tumor size and location.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Michael J. Cavnar, Kenneth Seier, Christina Curtin, Vinod P. Balachandran, Daniel G. Coit, Sam S. Yoon, Aimee M. Crago, Vivian E. Strong, William D. Tap, Mithat Gonen, Cristina R. Antonescu, Murray F. Brennan, Sam Singer, Ronald P. DeMatteo
Summary: Surgery for gastrointestinal stromal tumor (GIST) in the imatinib era has resulted in prolonged overall survival compared to the pre-imatinib era. Tumor site, size, and mitotic rate in pre-imatinib era primary tumor patients are associated with survival. Imatinib treatment may benefit patients with high-risk features, particularly tumor size.
Article
Gastroenterology & Hepatology
Michael J. Cavnar, Kenneth Seier, Mithat Gonen, Christina Curtin, Vinod P. Balachandran, William D. Tap, Cristina R. Antonescu, Sam Singer, Ronald P. DeMatteo
Summary: In primary GIST undergoing Neo-IM therapy, progression was uncommon, but substantial down-sizing occurred in the minority. High tumor mitotic rate and incomplete resection following Neo-IM were associated with poor outcome, while adjuvant imatinib was associated with prolonged survival.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Oncology
Marya Kozinova, Shalina Joshi, Shuai Ye, Martin G. Belinsky, Dinara Sharipova, Jeffrey M. Farma, Sanjay S. Reddy, Samuel Litwin, Karthik Devarajan, Alex Rosa Campos, Yi Yu, Brian Schwartz, Margaret von Mehren, Lori Rink
Summary: This study evaluated the combination of a novel AKT inhibitor, MK-4440, with imatinib mesylate (IM) in gastrointestinal stromal tumor (GIST) cells and preclinical models. The results demonstrated synergistic effects of dual inhibition of KIT and AKT in both IM-sensitive and -resistant GIST cell lines, with enhanced cell death through cell cycle arrest and increased PDCD4 expression. In vivo studies showed superior efficacy of the MK-4440/IM combination in IM-sensitive GIST models, suggesting potential clinical benefits in primary GIST treatment.
Article
Oncology
Sara Renberg, Yifan Zhang, Fredrik Karlsson, Robert Branstrom, Jan Ahlen, Li Jalmsell, Christina Linder-Stragliotto, Felix Haglund de Flon, Andri Papakonstantinou
Summary: This retrospective study investigated the use of neoadjuvant imatinib in patients with gastrointestinal stromal tumors (GIST), showing that it can effectively reduce tumor size and minimize the extent of surgery, especially for tumors in the stomach or small intestine.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Medicine, General & Internal
Tingting Wu, Xiaobin Cheng, Wenbin Chen
Summary: Surgery remains the mainstay of treatment for rectal GIST patients who achieve clinical complete response (cCR) after imatinib therapy, while close follow-up and continuous imatinib treatment are necessary for patients who cannot undergo surgery.
Review
Cell Biology
Jiehan Li, Shuning Guo, Zhenqiang Sun, Yang Fu
Summary: In this review, the role of noncoding RNAs (ncRNAs) in drug resistance of gastrointestinal stromal tumor (GIST) was summarized. The study found that ncRNAs play important roles in the resistance of GIST, mainly through regulating mechanisms such as oxidative phosphorylation, autophagy, apoptosis, drug target changes, and signaling pathways.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Multidisciplinary Sciences
Christina M. Sheedy, Anna Weinstein, Olivia Chafitz, Antonia F. Oladipo
Summary: This study reports a rare case of gastrointestinal stromal tumor in the first trimester of pregnancy, and highlights the importance of early diagnosis of GIST during pregnancy.
Article
Multidisciplinary Sciences
Tahsin M. Khan, Emily A. Verbus, Alexander J. Rossi, Jonathan M. Hernandez, Jeremy L. Davis, Brian A. Coakley, Andrew M. Blakely
Summary: Wild-type KIT and PDGFRA gastrointestinal stromal tumors are rare and have limited treatment options. This study analyzed data from a large national database to identify factors influencing overall survival, finding that tumors in the small intestine and with high mitotic count were associated with decreased OS. Surgery remains the primary treatment modality for wild-type GIST.
SCIENTIFIC REPORTS
(2022)
Article
Genetics & Heredity
Lei Cao, Kunming Zheng, Yanhong Liu, Peng Song, Chuntao Wang, Hongzhi Wang, Nan Wang, Shiwu Zhang, Yongjie Zhao
Summary: This study identified 897 differentially expressed genes (DEGs) between imatinib-sensitive and imatinib-resistant cell lines of GIST using RNA sequencing. Among the DEGs, 10 top genes (NDN, FABP4, COL4A1, COLEC11, MEG3, EPHA3, EDN3, LMO3, RGS4, and CRISP2) were selected and their expression trends in different imatinib-resistant cell lines were confirmed using RT-PCR. These findings suggest that these genes may potentially play a role in the clinical diagnosis and treatment of imatinib resistance in GIST.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Cesar Serrano, Rosa Alvarez, Juan Antonio Carrasco, Gloria Marquina, Jeronimo Martinez-Garcia, Virginia Martinez-Marin, Maria angeles Sala, Ana Sebio, Isabel Sevilla, Javier Martin-Broto
Summary: Gastrointestinal stromal tumor (GIST) is a common malignant neoplasm of mesenchymal origin, and a successful model for targeted cancer therapies. The use of tyrosine kinase inhibitors targeting KIT/PDGFRA has greatly improved survival in both localized and advanced stages, despite previous resistance to systemic therapies. These guidelines, developed by the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS), provide an updated consensus for diagnosing and treating GIST patients, emphasizing the importance of multidisciplinary teams in specialized centers.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Mahmoud Mohammadi, Hans Gelderblom
Summary: The discovery of oncogenic mutations in the KIT and PDGFRA tyrosine kinase receptor was a crucial step in the development of tyrosine kinase inhibitors (TKIs). GIST became a model for molecular-targeted therapy, leading to improved overall survival, but further progress is needed for TKI resistant mutations. Combination therapies and immunotherapy have not fully delivered on their promise in GIST. The development of novel approved TKIs like ripretinib and avapritinib, as well as NTRK inhibitors for ultrarare NTRK fusions, highlight the ongoing need for adequate molecular profiling of high-risk GISTs before treatment.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Oncology
Maria Susanna Grimaudo, Alice Laffi, Nicolo Gennaro, Roberta Fazio, Federico D'Orazio, Laura Sama, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi
Summary: This case series describes the experience of using a personalized daily continuous administration of Regorafenib as an alternative regimen for treating metastatic GIST patients. The results show that this personalized schedule is safe and effective for these patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Takuma Hayashi, Ikuo Konishi
Summary: Through cancer genome testing, a germline pathogenic variant of the KIT gene was detected in a 32-year-old male patient with advanced GISTs, confirming the diagnosis of familial multinodular GIST. Treatment with imatinib resulted in long-term regression of GISTs in this patient. Therefore, cancer genome testing can be used to diagnose malignant tumors and select new therapeutic agents for advanced malignancies.
Article
Mathematics, Applied
Sebastian Burciu
Summary: In this paper, it is shown that integral fusion categories with rational structure constants have a natural group of symmetries, given by the Galois group of their character tables. These symmetries are then used to generalize a well-known result of Burnside in the representation theory of finite groups. The main result establishes that any row in the character table of a weakly integral fusion category, corresponding to a non-invertible object, contains a zero entry.
JOURNAL OF ALGEBRA AND ITS APPLICATIONS
(2023)
Article
Mathematics, Applied
Sebastian Becker, Benjamin Gess, Arnulf Jentzen, Peter E. Kloeden
Summary: This article demonstrates strong convergence rates for fully discrete numerical approximations of space-time white noise driven SPDEs with superlinearly growing nonlinearities, such as the stochastic Allen-Cahn equation with space-time white noise. The obtained strong rates of convergence are essentially sharp.
STOCHASTICS AND PARTIAL DIFFERENTIAL EQUATIONS-ANALYSIS AND COMPUTATIONS
(2023)
Article
Mathematics
S. Baader, P. Feller, L. Ryffel
Summary: This article characterizes the conditions under which a set of simple closed curves forms a bouquet on an orientable surface, based on the relationships between the corresponding Dehn twists.
GLASGOW MATHEMATICAL JOURNAL
(2023)
Article
Oncology
Monika Scheer, Erika Hallmen, Christian Vokuhl, Joerg Fuchs, Per-Ulf Tunn, Marc Muenter, Beate Timmermann, Sebastian Bauer, Anton George Henssen, Bernarda Kazanowska, Felix Niggli, Ruth Ladenstein, Gustaf Ljungman, Angelika Eggert, Thomas Klingebiel, Ewa Koscielniak
Summary: This study evaluated the effects of neoadjuvant or adjuvant radiation therapy and surgery only on long-term outcomes in patients with synovial sarcoma. The results showed that the best local control was achieved when tumors were irradiated pre-operatively and underwent R0 or R1 resection thereafter.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lazaros Lazaridis, Teresa Schmidt, Christoph Oster, Tobias Blau, Daniela Pierscianek, Jens T. Siveke, Sebastian Bauer, Hans-Ulrich Schildhaus, Ulrich Sure, Kathy Keyvani, Christoph Kleinschnitz, Martin Stuschke, Ken Herrmann, Cornelius Deuschl, Bjorn Scheffler, Sied Kebir, Martin Glas
Summary: The study analyzed the clinical course of 41 patients with relapsed brain cancer and found that molecularly matched targeted therapy can provide longer progression-free survival and overall survival for some patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Silvia Stacchiotti, Hans Roland Duerr, Inga-Marie Schaefer, Klaus Woertler, Rick Haas, Annalisa Trama, Augusto Caraceni, Jyoti Bajpai, Giacomo Giulio Baldi, Nicholas Bernthal, Jean-Yves Blay, Kjetil Boye, Javier-Martin Broto, Wei-Wu Tom Chen, Paolo Angelo Dei Tos, Jayesh Desai, Stephan Emhofer, Mikael Eriksson, Alessandro Gronchi, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, John Healey, Antoine Italiano, Robin L. Jones, Akira Kawai, Andreas Leithner, Herbert Loong, Eric Mascard, Carlo Morosi, Nadine Otten, Emanuela Palmerini, Shreyaskumar R. Patel, Peter Reichardt, Brian Rubin, Piotr Rutkowski, Claudia Sangalli, Kathrin Schuster, Beatrice M. Seddon, Morena Shkcodra, Eric L. Staals, William Tap, Matt van de Rijn, Kirsten van Langevelde, Filip M. M. Vanhoenacker, Andrew Wagner, Lisette Wiltink, Sydney Stern, Michiel Van de Sande, Sebastian Bauer
Summary: Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive tumor that arises from the joints, bursa, and tendon sheaths. There are two types of TGCT: nodular and diffuse, with the former exhibiting a slow disease course and the latter showing locally aggressive behavior. Although not life-threatening, TGCT can cause chronic pain and negatively impact function and quality of life. CSFR1 inhibitors are effective in treating TGCT but are not widely available. The lack of guidelines and uncertainty in selecting appropriate therapy lead to inconsistent adoption of new treatments and suboptimal outcomes for patients. A global consensus meeting was held in June 2022 to develop evidence-based recommendations for the optimal management of TGCT.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This article describes the impact of Tenosynovial giant cell tumor (D-TGCT) on patient-reported outcomes (PROs) based on the Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry. The study found that patients without active treatment strategy had lower pain levels and better quality of life at 1-year and 2-year follow-ups. On the other hand, patients receiving systemic treatment had higher pain levels when they changed treatment strategies. These findings highlight the significant impact of treatment strategies on patient quality of life.
Article
Cardiac & Cardiovascular Systems
Denis Fedorov, Robert Bauernschmitt, Jean-Pilippe Grunebaum, Stefan Bauer, Ralf Sodian, Eberhard von Hodenberg
Summary: This study aimed to evaluate the outcomes of redo-SAVR and TAVI-VIV for degenerated stentless bioprostheses. The results showed outstanding 30-day and 1-year survival rates for both procedures. Isolated redo-SAVR may be preferred in younger patients due to lower pacemaker implantation rates, while TAVI-VIV could be a method of choice for elderly patients with high operative risk.
THORACIC AND CARDIOVASCULAR SURGEON
(2023)
Correction
Multidisciplinary Sciences
Mario Mech, Andre Ehrlich, Andreas Herber, Christof Luepkes, Manfred Wendisch, Sebastian Becker, Yvonne Boose, Dmitry Chechin, Susanne Crewell, Regis Dupuy, Christophe Gourbeyre, Joerg Hartmann, Evelyn Jaekel, Olivier Jourdan, Leif-Leonard Kliesch, Marcus Klingebiel, Birte Solveig Kulla, Guillaume Mioche, Manuel Moser, Nils Risse, Elena Ruiz-Donoso, Michael Schaefer, Johannes Stapf, Christiane Voigt
Editorial Material
Medicine, General & Internal
Stefan Bauer, Lukas Ernstbrunner
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Stefan Bauer, William G. G. Blakeney, Allan W. W. Wang, Lukas Ernstbrunner, Jocelyn Corbaz, Jean-David Werthel
Summary: In this second part of the comprehensive review on the optimization of reverse shoulder arthroplasty (RSA), three other challenges are focused on: 1. Conservation of sufficient subacromial and coracohumeral space; 2. Scapular posture; and 3. Moment arms and muscle tensioning. The implications of these challenges are essential to optimize RSA function and improve active force generation. Understanding and addressing these challenges can help prevent complications and guide further research in the field of RSA optimization.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
C. Serrano, S. Bauer, D. Gomez-Peregrina, Y. -K Kang, R. L. Jones, P. Rutkowski, O. Mir, M. C. Heinrich, W. D. Tap, K. Newberry, A. Grassian, H. Shi, S. Bialick, P. Schoffski, M. A. Pantaleo, M. von Mehren, J. C. Trent, S. George
Summary: This study used ctDNA sequencing to analyze the impact of KIT/PDGFRA gene mutations on TKI resistance and evaluate its clinical validity and utility. The results showed that ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict the treatment response of GIST patients to avapritinib.
ANNALS OF ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Celina Tretter, Niklas de Andrade Kraetzig, Matteo Pecoraro, Sebastian Lange, Philipp Seifert, Clara von Frankenberg, Johannes Untch, Gabriela Zuleger, Mathias Wilhelm, Daniel P. P. Zolg, Florian S. S. Dreyer, Eva Braeunlein, Thomas Engleitner, Sebastian Uhrig, Melanie Boxberg, Katja Steiger, Julia Slotta-Huspenina, Sebastian Ochsenreither, Nikolas von Bubnoff, Sebastian Bauer, Melanie Boerries, Philipp J. J. Jost, Kristina Schenck, Iska Dresing, Florian Bassermann, Helmut Friess, Daniel Reim, Konrad Gruetzmann, Katrin Pfuetze, Barbara Klink, Evelin Schroeck, Bernhard Haller, Bernhard Kuster, Matthias Mann, Wilko Weichert, Stefan Froehling, Roland Rad, Michael Hiltensperger, Angela M. M. Krackhardt
Summary: RNA variants resulting from cancer-associated RNA editing events can serve as a potential source of neoantigens. The authors use a comprehensive proteogenomic pipeline to identify and validate neoantigen candidates in patients with different tumor types, highlighting the importance of RNA as a significant source of neoantigens. Systemic pan-tumor analyses can provide insights into common features associated with cancer immunogenicity and patient survival.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Lennart Schardt, Moritz Kaths, Sebastian Bauer
Summary: Summary: Gastrointestinal stromal tumors (GIST) consist of various molecular subtypes with different treatment implications. Genotyping plays a crucial role in treatment decision-making. Adjuvant imatinib treatment is beneficial for patients with KIT exon 11 mutations and high risk of relapse. Evidence for this benefit is weaker for less frequent KIT genotypes, such as exon 9, 13, and 17 mutations. Neoadjuvant treatment is important in imatinib-sensitive subtypes with significant surgery-related morbidity. Multimodal treatment may be considered for metastatic patients with potential complete resection. Next generation inhibitors like ripretinib and avapritinib show promising results in pretreated GIST and GIST with PDGFRA mutations, but the role of multimodal approaches in these settings is yet to be determined.
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This study investigated the impact of diffuse-type Tenosynovial giant cell tumor (D-TGCT) on treatment strategies and quality of life for patients. The results showed that patients who switched to an active treatment strategy had higher scores for pain and interference, while patients who remained off-treatment had lower scores at the 2-year follow-up. These findings are important for guiding the treatment and management of D-TGCT.
